Related Experiment Video

Updated: May 29, 2026

A Neonatal Rodent Model of Retroorbital Vein Injection
04:39

A Neonatal Rodent Model of Retroorbital Vein Injection

Published on: February 23, 2024

Neonatal drug development

Mark A Turner1

  • 1Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, United Kingdom. Mark.turner@liverpool.ac.uk

Early Human Development
|September 20, 2011
PubMed

Insights

Regulatory pressures are improving drug development for neonates. This paper examines challenges in creating new medicines and how current strategies can enhance research on existing neonatal drugs.

Area of Science:

  • Neonatal pharmacology
  • Pediatric drug development
  • Regulatory science

Background:

  • Drug development for neonates is essential for advancing medical care.
  • Regulatory agencies increasingly emphasize improved pharmaceutical practices for this population.
  • This focus creates new avenues for neonatal research and therapeutic innovation.

Purpose of the Study:

  • To outline the challenges encountered in developing new drugs for neonates.
  • To explore how modern drug development approaches can inform research into existing neonatal medications.

Main Methods:

  • Literature review of drug development processes.
  • Analysis of regulatory impacts on pharmaceutical research.
  • Comparative assessment of new versus existing drug research strategies.

Main Results:

  • Identification of key issues in neonatal drug development.
  • Demonstration of regulatory influence on pharmaceutical company practices.
  • Framework for applying new drug development insights to existing drugs.

Conclusions:

  • Enhanced regulatory oversight positively impacts neonatal drug development.
  • Contemporary drug development methodologies offer valuable insights for optimizing existing neonatal treatments.
  • Further research is needed to fully leverage these opportunities for improved neonatal care.

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...